



BEST AVAILABLE COPY

Figure 1




BEST AVAILABLE COPY

Figure 2







BEST AVAILABLE COPY

Figure 3







BEST AVAILABLE COPY

F1 e 4



BEST AVAILABLE COPY

Figure 5

A Non-fed**B** Non-fed**C**Fed MBP**D**Fed MBP

BEST AVAILABLE COPY







Fig. 6

BEST AVAILABLE COPY






Fig 10

MBP-Peptides triggering MBP-fed spleen cells to Suppress OVA-line in TW system





Fig 11

CLINICAL DATA FROM SJL/J MICE EAE STUDY
#33/N8 (1/29/92), IMMUNIZED WITH PLP (140-160)/CFA ON DAY 0&7.


BEST AVAILABLE COPY

A



Q

GROUP




BEST AVAILABLE COPY

Fig 13

CLINICAL DATA FROM SJL/J MICE EAE STUDY

#33/N8 (1/29/92), IMMUNIZED WITH PLP(140-160)/CFA ON DAY 0&7.



B


GROUP

BOVINE PLP 0.25mg IV

■ MEAN CLINICAL SCORE

MOUSE MBP 0.25mg IV

HISTONE 0.25mg IV



BEST AVAILABLE COPY

Suppression of ETE induced by 71-90
by feeding various peptides





Fig. 14

BEST AVAILABLE COPY



Suppression of EAE by i.v. tolerization with MBP and MBP-peptides prior to disease expression(days 8' and, 9' post immunization)

